Piper Jaffray Downgrades Endocyte (ECYT) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
Endocyte (ECYT) Removed from Wedbush's Best Ideas List
May 5, 2014 10:21 AM EDTWedbush maintained an Outperform rating on Endocyte (NASDAQ: ECYT) but removed the stock from its Best Ideas List. Its price target was reduced to $26.00 (from $65.00).
Analyst Gregory R. Wade said, "The Data Safety... More
Baird Downgrades Endocyte (ECYT) to Neutral
May 2, 2014 10:17 AM EDTBaird downgraded Endocyte (NASDAQ: ECYT) from Outperform to Neutral with a price target of $8.00.
For an analyst ratings summary and ratings history on Endocyte click here. For more ratings news on Endocyte click here.
Shares of Endocyte closed at $17.38 yesterday.
... MoreEndocyte, Inc. (ECYT) Tops Q1 EPS by 5c; Reports Halt of PROCEED Trial (MRK)
May 2, 2014 8:02 AM EDTEndocyte, Inc. (NASDAQ: ECYT) reported Q1 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $17.3 million versus the consensus estimate of $15.07 million.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and... More
